Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer By Ogkologos - November 18, 2024 719 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing Abemaciclib Improves PFS at Six Months Among Patients with High-Grade Meningiomas Harbouring NF2 or CDK Pathway Alterations MOST POPULAR Quitting Smoking Improves Survival in People with Lung Cancer September 14, 2021 Screen-Detected Colorectal Cancers Have a More Favourable Stage Distribution than Colorectal... May 20, 2022 Zooming in: Fine-tuning the picture to diagnose oesophageal cancer earlier August 10, 2021 Young Woman’s Breast Cancer Diagnosis Ends Up Saving Her Mom’s Life... September 27, 2021 Load more HOT NEWS Indigenous Women with Early Stage Breast Cancer Get Mastectomies at Higher... Malaria Vaccine Approved by W.H.O. Could Save Tens Of Thousands Of... ‘Being open will help bring awareness’: Meet the fashion vlogger who... Opinion: “There’s cause for optimism in 2021 and beyond”
